1Lipschutz JH, Li S, Arisco A, et al. Extraeellular signalregulated kinases 1/2 control elaudin-2 expression in Madin- Darby canine kidney strain Ⅰ and Ⅱ eells[J]. J Biol Chem, 2005,280(5) : 3780-3788.
2Koyama J, Yokouchi K, Fukushima N, et al. Neurotrophic effect of hepatocyte growth factor on neonatal facial motor neurons [J]. Neurol Res, 2003,25 (7) : 701-707.
3Wang X, Zhou Y, Kim HP, et al. Hepatocyte growth factor protects against hypoxia /reoxygenation-indueed apoptosis in endothelial cells[J]. J Biol Chem,2004,279(7) :5237-5243.
4Nakagami H, Morishita R, Yamamoto K, et al. Phosphorylation of p38 mitogen-activated protein kinase downstream of baxcaspase-3 pathway leads to cell death induced by high Dglucose in human endothelial cells[J]. Diabetes,2001,50(6): 1472-1481.
5Taniyama Y, Morishita R, Hiraoka K, et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model:molecular mechanisms of delayed angiogenesis in diabetes[J]. Circulation, 2001,104 (19) :2344-2350.
8Jakus V, Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications [J]. Physiol Res,2004,53(2) :131-142.
9Gopalkrishnapillai B, Nadanathangam V, Karmakar N, et al. Evaluation of autofluorescent property of hemoglobin-advanced glycation end product as a long-term glycemic index of diabetes [J]. Diabetes, 2003,52 (4) : 1041-1046.
1Peppa M, Uribarri J, Vlassara H. The role of advanced glycation end products in the development of atherosclerosis [ J ]. Curt Diab Rep, 2004, 4( 1 ) :31-36.
2Panagiotopoulos S, OBrien RC, Bucala R, et al. Aminoguanidine has an anti -atherogenic effect in the cholesterol-fed rabbit[ J]. Atherosclerosis, 1998, 136( 1 ) :125-131.
3Kanauchi M, Tsujimoto N, Hashimoto T. Advanced glycation end products in nondiabetic patients with coronary artery dinsease [ J ].Diabetes Care, 2001, 24 ( 9 ) : 1620-1623.
4Lin RY, Choudhury RP, Cai W, et al. Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice[ J]. Atherosclerosis, 2003, 168(2): 213-220.
5Forbes JM, Thallas V, Thomas MC, et al. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes [ J ]. FASEB J, 2003, 17(12) : 1762-1764.
6Gardiner TA, Anderson HR, Stitt AW. Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes [ J ]. J Pathol, 2003,201(2): 328-33.
7Heidland A, Sebekova K, Schinzel R. Advanced glycation end products and the progressive course of renal disease[ J]. Am J Kidney Dis, 2001, 38(4 Suppl 1): S100-106.
8Friedlander MA, Witko-Sarsat V, Nguyen AT, et al. The advanced glycation endproduct pentosidine and monocyte activation in uremia[J]. Clin Nephrol, 1996, 45(6) : 379-382.
9Miyata T, Saito A, Kurokawa K, et al. Advanced glycation and lipoxidation end products: reactive carbonyl compounds-related uraemic toxicity[ J]. Nephrol Dial Transplant, 2001,16 ( Suppl 4) :8-11.
10Cartledge JJ, Eardley I, Morrison JF. Advanced glycation endproducts are responsible for the impairment of corpus cavemosal smooth muscle relaxation seen in diabetes[J]. BJU Int, 2001, 87(4) :402-407.
